85526-38-1

Upstream product

• 462-08-8 pyridin-3-ylamine 
• 67-66-3 chloroform 
• 22236-96-0 3-N-formylaminopyridine 

Downstream Products

• 85526-42-7 N³-(4-Methylphenyl)-N²-(3-pyridinyl)phenanthro<9,10-b>furan-2,3-diimin 
• 119541-42-3 N-Pyridin-3-yl-cyclohexanecarboximidothioic acid pyridin-2-yl ester 
• 1261117-48-9 C₁₇H₁₆FN₅ 
• 1261110-02-4 2-amino-1-(2-(4-fluorophenyl)-3-(pyridin-3-ylamino)-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-2-methylpropan-1-one 
• 1351990-71-0 3-(4-phenyl-1H-imidazol-1-yl)pyridine 
• 119520-52-4 N-(pyridin-3-yl)cyclohexanecarboxamide 
• 58086-71-8 2-phenethylthiomethylpyridine 
• 119541-41-2 3-Phenyl-N-pyridin-3-yl-thiopropionimidic acid pyridin-2-yl ester 

Relevant academic research and scientific papers

Application of proteasome inhibitor in inhibition of novel coronavirus

The invention provides application of a proteasome inhibitor in inhibition of a novel coronavirus or preparation of novel coronavirus inhibitors. The proteasome inhibitor has a structure represented by a formula (I) or isomers, pharmaceutically acceptable salts thereof and prodrugs thereof. According to the application, by applying the proteasome inhibitor to inhibition of the novel coronavirus, good inhibiting activity is obtained, and a novel treatment way of think is provided for diseases such as pneumonia caused by the novel coronavirus.

TETRAHYDROISOQUINOLINES CONTAINING SUBSTITUTED AZOLES AS FACTOR XIA INHIBITORS

The present invention provides compounds of Formula (I), or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

THE INVENTION OF RADICAL REACTIONS PART XVIII. A CONVENIENT SOLUTION TO THE 1-CARBON PROBLEM (R-CO2H --> R-13CO2H)

Radicals generated by photolysis (W light) of esters derived from N-hydroxy-2-thiopyridone react with electrophilic isocyanides 2a and (in the presence of trifluoroacetic acid) 2b to give adducts of type 3.Convenient reaction procedures have been worked out to hydrolyse the adducts to amides of type 5, from which the original acid can be regenerated under mild conditions.The three important acids oleic, linoleic and arachidonic have all given smooth reactions.In suitable examples, quantitative evolution of carbon dioxide and incorporation of 13C without dilution have been demonstrated.This reaction sequence will be useful for the labelling in the carboxyl group of prostaglandins, leukotrienes, and the side chain carboxyls of peptides.